doi: 10.1016/j.cmet.2018.03.001 [DOI] [PubMed] [Google Scholar] 2.Holt MK, Richards JE, Cook DR, et al
Ive been eating alot less on a GLP1 so when I do eat I make sure its higher in protein and fiber
Recent studies show that GLP-1(936) can activate the inhibitory G protein (Gi/o), leading to the translocation of secretory granules (SG) beneath the cell membrane, thereby inhibiting glucagon secretion
California is joining several other states in restricting an option they say is no longer affordable as they confront soaring pharmaceutical costs and steep Medicaid cuts under the Trump administration, among other financial pressures
Ideal candidates are individuals who have lost significant weight or are dealing with loose skin due to aging
Jenn and I discuss: How natural GLP-1 production can decline with age Why under-fueling is still the primary issue for many athletes Different types and forms of GLP-1 meds Who should (and shouldn't) consider these medications Potential risks of GLP-1 use, including muscle loss, bone density loss, and GI distress Potential benefits to inflammation, autoimmune conditions, gut health, and mood Nutrition and supplement strategies when appetite is lower Dosing and microdosing for therapeutic use, not just weight loss Why some athletes cycle on and off these meds, or may only need them for a short period of time Why Jenn takes most clients off GLP-1s during race training The stigma around GLP-1 use among athletes Jenn's own story: early menopause, a cardiovascular family history, and how a short course changed her running Why solid diet and lifestyle habits must always come first I hope this episode helps you better understand the complexities of GLP-1 medications in endurance athletes, and why there's rarely a simple yes-or-no answer to the questions we explore together
00197-4/asset/bc822c6e-5915-4cb3-97bc-7187c857a496/main.assets/gr1_lrg.jpg)
02105-1/asset/8468e457-0c7f-4e4c-9b6d-2202dbefa9cb/main.assets/gr1_lrg.jpg)
